MaxCyte, Inc. (MXCT) Fair Value 2026

MXCT · Medical Devices ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

7.0 /10

32 fundamental signals · 1 models active

Value Trap Risk

LOW (35/100)

Quick Summary — As of 2026-08-27, MaxCyte, Inc. (MXCT) trades at $1.28. QOC: 7.0/10. Value Trap Risk: 35/100 (LOW). 1/13 models active.

Key Facts

Ticker
MXCT
Price
$1.28
Quality Score
7.0/10
Value Trap Risk
35/100
Models Active
1/13
Last Updated
Strength: 1 independent models provide multi-angle coverage
Risk: Majority of models suggest overvaluation

What Fair Value Does Each Model Give MXCT?

1 Intrinsic Value Models vs. Current Price ($1.28)

Core Models (Unlocked)
Model Fair Value Upside
Asset-Based · High Conviction
 $0.85 -33.8%

All Models Active

All 1 models are displayed above.

What Is MaxCyte, Inc. (MXCT) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, MaxCyte, Inc.'s intrinsic value is estimated at $0.85. Trading at its current price of $1.28, the valuation engine raises significant caution: 1 of 1 models flag downside risk, projecting a median implied return of -33.8%.

What Do the Models Say About MXCT?

1 of 13 models are currently active for MXCT. All 1 active models suggest the stock trades above fair value. See which stocks rank higher →

How Does MXCT Rank in Medical Devices?

Among 157 Medical Devices stocks, MXCT ranks #50 by Quality of Company score. CirclFi's QOC score of 7.0/10 evaluates 32 fundamental signals. A score of 7.0 indicates above-average quality.

See all Most Undervalued Medical Devices Stocks →

MaxCyte, Inc.'s positioning within the Medical Devices segment means that revenue per drug plays an outsized role in fundamental analysis. The sector's unique characteristics — including therapeutic area leadership — shape both the opportunity set and risk profile.

Is MXCT a Value Trap?

CirclFi's Value Trap algorithm assigns MXCT a score of 35/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

1 of 13 models are active for MaxCyte, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, MaxCyte, Inc. earns a quality score of 7.0/10. This respectable rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every MXCT valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across MXCT's 1 active models, average confidence is 52%. Moderate confidence indicates reasonable fit.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy MaxCyte, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Medical Devices Stocks Should You Also Analyze?

11 related Medical Devices stocks with 13-model coverage

ESTAEstablishment Labs Holdings Inc.QOC 7.0PRCTPROCEPT BioRobotics CorporationQOC 6.9MASS908 Devices Inc.QOC 7.1CERSCerus CorporationQOC 6.9IRTCiRhythm Holdings, Inc.QOC 7.1CTKBCytek Biosciences, Inc.QOC 6.9AIDX20/20 Biolabs, Inc.QOC 6.0TRIBTrinity Biotech plcQOC 4.8BSXBoston Scientific CorporationQOC 8.9IRMDIRADIMED CORPORATIONQOC 9.8PODDInsulet CorporationQOC 9.6

Read investment analysis: ESTA · PRCT · MASS · CERS · IRTC · CTKB · AIDX · TRIB · BSX · IRMD · PODD

Which Other Stocks Have a Similar Quality Score to MXCT?

7 companies across all industries closest to MXCT’s Quality of Company score of 7.0/10.

JEFJefferies Financial Group Inc.QOC 7.0LQDALiquidia CorporationQOC 7.0MRNAModerna, Inc.QOC 7.0ARWArrow Electronics, Inc.QOC 7.0TALKTalkspace IncQOC 7.0HKDAMTD Digital Inc.QOC 7.0NVDANVIDIA CorporationQOC 10.0

Read investment analysis: JEF · LQDA · MRNA · ARW · TALK · HKD · NVDA

Where Does MXCT Sit in CirclFi's Medical Devices Rankings?

MXCT is ranked against every other Medical Devices stock CirclFi covers in each of these screens.

See all Medical Devices stocks ranked →

What Else Do Investors Ask About MaxCyte, Inc.’s Valuation?

What is MaxCyte, Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for MaxCyte, Inc. (MXCT). The Quality of Company score is 7.0/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is MXCT overvalued or undervalued right now?

At $1.28, 0 of 1 active models suggest MXCT may be undervalued, while 1 indicate potential overvaluation. The assessment depends on which methodology best fits MaxCyte, Inc.'s business model in Medical Devices.

What does a Quality of Company score of 7.0 mean for MXCT?

MaxCyte, Inc.'s QOC of 7.0/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores above 7 indicate strong fundamentals and disciplined management.

How many valuation models does CirclFi run on MXCT?

CirclFi analyzes MXCT with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 1 of 13 are active for this stock. Read the full methodology →

Is MXCT a value trap in 2026?

MaxCyte, Inc.'s Value Trap score is 35/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns MaxCyte, Inc. (MXCT) a Quality of Company score of 7.0/10 across 32 fundamental signals as of 2026-08-27.” Source: circlfi.com/stock/MXCT/ · Methodology
Primary sources for this MXCT valuation
  • Financial statements: MaxCyte, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001287098) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for MXCT as of ; valuations recomputed .